Dyslipidemias

Company earns $1.0 million milestone payment related to GW501516

Published in Drug Week, July 16th, 2004

Ligand Pharmaceuticals, Inc., (LGND) has earned a $1.0 million milestone payment from GlaxoSmithKline (GSK) as a result of GSK's decision to continue phase II development of GW501516, a novel peroxisome proliferation-activated receptor (PPAR) modulator for the treatment of dyslipidemias.

Dyslipidemias include elevated LDL (bad) cholesterol, low HDL (good) cholesterol, and/or elevated triglycerides, all of which increase the risk of cardiovascular disease, the leading cause of death in the United States. Although widely used drugs such as statins lower LDL cholesterol effectively, they are less efficacious at improving other lipid profiles.

PPARs are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-07-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry